Just days after divesting its psoriasis drug Otezla® (apremilast) to Amgen in exchange for US$13.4 B, Celgene has agreed to collaborate with Immatics Biotechnologies to discover and develop T-cell redirecting cancer immunotherapies. The deal, worth up to US$1.6 B, gives Celgene options to up to three adoptive cell therapies that utilise Immatics’ Xpresident® technology, and expands Celgene’s immuno-oncology focus beyond mainly chimeric antigen receptor T-cell based treatments.